Q-omics provides the consensus-scored THRAP3P3 profile across patient tissues and cancer cell-line models. THRAP3P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, THRAP3P3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, THRAP3P3 RNA expression shows 8,660 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where THRAP3P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THRAP3P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THRAP3P3 survival associations across molecular data types. THRAP3P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THRAP3P3 RNA expression–survival associations across cancer types. High THRAP3P3 expression shows unfavorable associations in STAD, ACC, KIRP, LUAD and LIHC, but favorable associations in READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for THRAP3P3 RNA expression.
This table summarizes THRAP3P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for THRAP3P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THRAP3P3 shows lower tumor expression in KIRC, THCA and UCEC and higher tumor expression in LIHC, COAD and KICH. The KIRC box plot shows higher THRAP3P3 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p < 0.001).
This table shows molecular features associated with THRAP3P3 in patient tissues and cancer cell lines. In patient samples, THRAP3P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
